Health knowledge made personal
Join this community!
› Share page:
Search posts:

BioMS brings New hope for Multiple Sclerosis Patients with a progressive form this disease

Posted Nov 17 2009 10:20pm
The potential to capture the Progressive Multiple Sclerosis Market.
• Up to 75% of MS patients carry either HLA-DR2 or HLA-DR4 immune response genes.
• MBP8298 demonstrated statistically significant clinical results in patients with these genes.

Statistically Significant Results in Patients with HLA-DR2 or HLA-DR4 Genes
MBP8298 is entering late-stage trials in secondary progressive MS
BioMS Medical Corp. is a development stage company, with its primary focus being the development
and commercialization of a medical treatment for multiple sclerosis.

Click this link:
for further information

Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
Post a comment
Write a comment:

Related Searches